Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155.

@article{Takahashi2017IncreasedSC,
  title={Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155.},
  author={Naomi Takahashi and Makoto Sugaya and Hiraku Suga and Tomonori Oka and Makiko Kawaguchi and Tomomitsu Miyagaki and Hideki Fujita and Takashi Inozume and Shinichi Sato},
  journal={The Journal of investigative dermatology},
  year={2017},
  volume={137 8},
  pages={
          1766-1773
        }
}
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances. CD155 is expressed in various types of cancer, and this surface molecule on tumor cells functions either as a co-stimulatory molecule or a co-inhibitory molecule, depending on its receptor. CD226, a CD155 ligand, is mainly expressed on natural killer cells and CD8+ T cells, playing important roles in natural killer cell-mediated cytotoxicity. In… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…